Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basmisanil in cognitive impairment associated with schizophrenia
NCT02953639Phase 2Completed
- Sponsor
- Roche
- Start
- Nov 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of basmisanil in schizophrenia (3 arms), sponsored by Roche. Primary endpoint: MATRICS Consensus Cognitive Battery Neurocognitive Composite Score at 24 weeks. Started Nov 2016; status: completed.
02
Drugs
basmisanil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02953639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953639.